Abstracts tagged "C-reactive protein (CRP)"

Abstract Number: 661 • 2012 ACR/ARHP Annual Meeting
Co-Localization of C-Reactive Protein, Immunoglobulin G and Complement in Renal Subendothelial Immune Deposits of Proliferative Lupus Nephritis Detected Using Immunogold Electron Microscopy
Christopher Sjöwall¹, Anders I. Olin², Thomas Skogh³, Jonas Wetterö⁴, Mattias Mörgelin², Ola Nived⁵, Gunnar Sturfelt⁶ and Anders A. Bengtsson⁷, ¹Deparment of clinical and experimental medicine, Linkoping University, Linkoping, Sweden, ²Infection Medicine, Department of Clinical Sciences, Lund University, Lund, Sweden, Lund, Sweden, ³Deparment of clinical and experimental medicine, Linköping University, Linköping, Sweden, ⁴Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden, ⁵Department of Rheumatology, University Hospital Lund, Lund, Sweden, ⁶Department of Clinical Sciences Lund, Section of Rheumatology, Lund University, Lund, Sweden, ⁷Department of Clinical Sciences, Section of Rheumatology, Lund University, Lund, Sweden
Background/Purpose: The pattern recognition molecules C-reactive protein (CRP) and complement protein 1q (C1q) are pivotal parts of the innate immune system and display relevant biological…
Abstract Number: 431 • 2012 ACR/ARHP Annual Meeting
Basic and Clinical Significance of Interleukin 6 (IL-6) in AA Amyloidosis with RA
Kazuyuki Yoshizaki, Prabha Tiwari, Lokesh P. Tripathi, Shandar Ahmad, Kenji Mizuguchi, Teppei Nishikawa-Matsumura, Tomoyasu Isobe and Soken-Nakazawa J. Song, Osaka University, Osaka, Japan
Background/Purpose: Cytokine-induced hepatic serum amyloid A (SAA) is associated with the pathogenesis of AA amylodosis, a fatal disease with deposition of AA amyloid fibril on…
Abstract Number: 2661 • 2012 ACR/ARHP Annual Meeting
Disease Activity Score 28-Joint Count: Are Erythrocyte Sedimentation Rate and C-Reactive Protein Versions Comparable?
Roy Fleischmann¹, Désirée van der Heijde², Andrew S. Koenig³, Ronald Pedersen³, Annette Szumski⁴, Lisa Marshall⁵ and Eustratios Bananis⁴, ¹Southwestern Medical Center at Dallas, University of Texas, Dallas, TX, ²Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Specialty Care, Pfizer Inc, Collegeville, PA, ⁴Specialty Care, Pfizer Inc., Collegeville, PA, ⁵Pfizer Inc., Collegeville, PA
Background/Purpose: Frequently DAS28-CRP is utilized instead of DAS28-ESR to assess rheumatoid arthritis (RA) disease activity; however, values for remission and low disease activity (LDA) for…
Abstract Number: 2382 • 2012 ACR/ARHP Annual Meeting
Plasma Fibrinogen is an Accurate Marker of Disease Activity in Patients with Polymyalgia Rheumatica
E.M. McCarthy¹, Paul A. MacMullan¹, S. Al-Mudhaffer¹, Anne M. Madigan¹, S. Donnelly¹, C. J. McCarthy¹, Dermot Kenny², Eamonn Molloy³ and G M. McCarthy¹, ¹Rheumatology, Mater Misericordiae University Hospital, Dublin 7, Ireland, ²Molecular and Cellular Therapeutics, RCSI, Dublin 2, Ireland, ³Rheumatology, Dublin Academic Medical Centre, St. Vincent's University Hospital, Dublin, Ireland
Background/Purpose: Accurate determination of disease activity in polymyalgia rheumatica(PMR) is challenging due to the subjective nature of symptoms and concurrent musculoskeletal complaints in an elderly…
Abstract Number: 2348 • 2012 ACR/ARHP Annual Meeting
Plasma Fibrinogen Better Identifies Persistent Disease Activity in Polymyalgia Rheumatica Than Either ESR or CRP
EM McCarthy¹, Paul A. MacMullan¹, S. Al-Mudhaffer¹, Anne M. Madigan¹, S. Donnelly¹, C. J. McCarthy¹, Dermot Kenny², Eamonn Molloy³ and G M. McCarthy¹, ¹Rheumatology, Mater Misericordiae University Hospital, Dublin 7, Ireland, ²Molecular and Cellular Therapeutics, RCSI, Dublin 2, Ireland, ³Rheumatology, Dublin Academic Medical Centre, St. Vincent's University Hospital, Dublin, Ireland
Background/Purpose: In PMR careful tailoring of the glucocorticoid dosage to the patients needs is crucial to avoid the risk of treatment-related adverse effects and the…
Abstract Number: 1344 • 2012 ACR/ARHP Annual Meeting
Diagnostic Value of High Sensitivity C Reactive Protein for Early Axial Spondyloarthritis: Results From the Devenir Des Spondylarthopathies Indifferenciees Recentes Cohort
Victoria Navarro-Compán¹, Désirée van der Heijde², Bernard Combe³, Claudine Cosson⁴ and Floris van Gaalen¹, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Deptartment of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Rheumatology, Hopital Lapeyronie, Montpellier, France, ⁴Biochemistry, Hôpital Bicêtre, Assistance Publique Hôpitaux de Paris, Paris, France
Background/Purpose: The average delay in spondyloarthritis (SpA) diagnosis after symptom onset is one of the longest among the inflammatory rheumatic diseases. Elevated C-reactive protein (CRP)…
Abstract Number: 1329 • 2012 ACR/ARHP Annual Meeting
Differential Effect of 4 and 8 Mg/Kg Tocilizumab in Combination with Methotrexate On Serum Biomarkers of Cartilage, Connective Tissue and Bone Turnover
Anne C. Bay-Jensen¹, Inger Byrjalsen², Andrew Kenwright³, Thierry Sornasse⁴, Claus Christiansen⁵ and Morten Asser Karsdal⁶, ¹Cartilage Biomarkers and Research, Nordic Bioscience, Herlev, Denmark, ²Research & Development, Nordic Bioscience, Herlev, Denmark, ³Roche, Welwyn Garden City, United Kingdom, ⁴Genentech, South San Francisco, ⁵CCBR, Ballerup, Denmark, ⁶Nordic Bioscience A/S, Herlev, Denmark
Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by poly-articular inflammation, cartilage loss, synovial inflammation, subchondral bone erosion, and joint space narrowing. In…
Abstract Number: 1296 • 2012 ACR/ARHP Annual Meeting
An Interim Analysis of the Efficacy of Abatacept in Japanese Biologics-naïve Rheumatoid Arthritis Patients (results from ABROAD study): Comparison of CRP and MMP-3 Level After Treatment with Abatacept Versus Anti-TNF Agents
Masahiro Sekiguchi¹, Kiyoshi Matsui¹, Masayasu Kitano¹, Mitsuo Namiki¹, Koichiro Ohmura², Takao Fujii³, Hideko Nakahara⁴, Keiji Maeda⁴, Hideo Hashimoto⁵, Takanori Kuroiwa⁶, Kenji Miki⁷, Masanori Funauchi⁸, Kazuhiro Hatta⁹, Kenshi Higami¹⁰, Shunzo Namiuchi¹¹, Ichiro Yoshii¹², Teruyuki Nakatani¹³, Takashi Ikawa¹⁴, Takaji Matsutani¹⁵, Kosaku Murakami¹⁶, Satoshi Morita¹⁷, Yutaka Kawahito¹⁸, Norihiro Nishimoto¹⁵, Tsuneyo Mimori¹⁹ and Hajime Sano¹, ¹Division of Rheumatology, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan, ²Department of Rheumatology & Clin Immunology, Kyoto University, Kyoto, Japan, ³Dept of Rheum/Clinical Immun, Graduate School of Medicine,, Kyoto University, Kyoto, Japan, ⁴Division of Allergy, Rheumatology and Connective Tissue Diseases, Department of Internal Medicine, NTT West Osaka Hospital, Osaka, Japan, ⁵Dept of Orthopedic Surgery, Rinku Hashimoto Rheumatology Orthopaedics, Osaka, Japan, ⁶Department of Rheumatology, Yukioka Hospital, Osaka, Japan, ⁷Department of Orthopaedic Surgery, Amagasaki Central Hospital, Amagasaki, Japan, ⁸Division of Hematology and Rheumatology, Department of Medicine, Kinki University Faculty of Medicine, Osaka, Japan, ⁹Department of Internal Medicine, Tenri Yorozu Sodansyo Hospital, Nara, ¹⁰Department of Rheumatology, Higami Hospital, Nara, Japan, ¹¹Department of Rheumatology, Saiseikai Nakatsu Hospital, Osaka, Japan, ¹²Department of Orthopaedic Surgery, Yoshii Hospital, Shimanto, Japan, ¹³Department of Orthopaedic Surgery, Kishiwada City Hospital, Osaka, Japan, ¹⁴Osaka Rehabilitation Hospital, Hannan, Japan, ¹⁵Laboratory of Immune Regulation, Wakayama Medical University, Ibaraki, Japan, ¹⁶Rheumatology and Clinical Immunology, Osaka Red Cross Hospital, Osaka, Japan, ¹⁷Graduate School of Medicine & Medical Center, Department of Biostatistics and Epidemiology, Yokohama City University, Kanagawa, Japan, ¹⁸Department of Inflammation and Immunology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan, ¹⁹Dept of Rheum & Clinical Immun, Kyoto University, Kyoto, Japan
Background/Purpose: Abatacept (ABA) is a recombinant fusion protein consisting of the extracellular domain of human CTLA-4, binding to CD80/86 on antigen presenting cells (APCs) and…
Abstract Number: 1270 • 2012 ACR/ARHP Annual Meeting
Role of Inflammation, Serologic Status and Low Density Lipoprotein in Coronary Heart Disease Among Patients with Rheumatoid Arthritis: Data From the National Veterans Health Administration
Iris Navarro-Millan¹, Shuo Yang², Scott L. DuVall³, Lang Chen⁴, John Baddley⁵, Grant W. Cannon⁶, Elizabeth S. Delzell⁷, Jie Zhang⁸, Monika M. Safford⁹, Nivedita M. Patkar¹⁰, Ted R. Mikuls¹¹, Jasvinder A. Singh¹² and Jeffrey R. Curtis⁸, ¹Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²Clinical Immunology/Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³VA Salt Lake City Health Care System and University of Utah School of Medicine, Salt Lake City, UT, ⁴Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁵Medicine, University of Alabama at Birmingham, Birmingham, AL, ⁶Division of Rheumatology, Salt Lake City VA and University of Utah, Salt Lake City, UT, ⁷Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ⁸Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁹Preventive Medicine, University of Alabama at Birmingham, Birmingham, AL, ¹⁰Immunology/Rheumatology, Univ of Alabama-Birmingham, Birmingham, AL, ¹¹Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ¹²Department of Medicine, University of Alabama, Tuscaloosa, AL
Background/Purpose: Rheumatoid arthritis (RA) increases the risk for coronary heart disease and ischemic events like myocardial infarction (MI). The association between traditional cardiovascular risk factors in…
Abstract Number: 832 • 2012 ACR/ARHP Annual Meeting
Peroxisome Proliferator-Activated Receptor Gamma Agonist Treatment for Rheumatoid Arthritis: A Proof-of-Concept Randomized Controlled Trial
Michelle J. Ormseth¹, Annette M. Oeser², Andrew Cunningham², Aihua Bian², Ayumi Shintani², S. Bobo Tanner³ and C. Michael Stein⁴, ¹Rheumatology, Vanderbilt Medical Center, Nashville, TN, ²Vanderbilt Medical Center, Nashville, TN, ³Div of Rheumatology & Allergy, Vanderbilt Medical Center, Nashville, TN, ⁴School of Medicine, Division of Clinical Pharmacology, Vanderbilt Medical Center, Nashville, TN
Background/Purpose: Rheumatoid arthritis (RA), a chronic inflammatory disease, is associated with insulin resistance. Experimental evidence indicates that the relationship between insulin resistance and inflammation is…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].